Dynavax Technologies is a commercial stage biopharmaceutical company focused on developing and commercializing vaccines. Co.'s primary marketed product, HEPLISAV-B® (Hepatitis B Vaccine (Recombinant), Adjuvanted), is approved by the United States Food and Drug Administration for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults approved in the United States. Co. also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Co. developed CpG 1018 to provide an increased vaccine immune response, as demonstrated in HEPLISAV-B. The DVAX stock yearly return is shown above.
The yearly return on the DVAX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the DVAX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|